Why the study?
Ivabradine is off-label and traditionally avoided in cardiogenic shock, but because it lacks negative inotropic action, it may offer a way to manage deleterious tachycardia in patients intolerant to beta-blockers.
Does ivabradine improve hemodynamics in patients with cardiogenic shock and sinus tachycardia who are intolerant to beta-blockers?
Does ivabradine improve hemodynamics in patients with cardiogenic shock and sinus tachycardia who are intolerant to beta-blockers?
In a small case series, ivabradine safely reduced heart rate and improved filling pressures without compromising cardiac index or mean arterial pressure in cardiogenic shock patients intolerant to beta-blockers.
No takes yet. Share an insight, caveat, or question.
Ivabradine in cardiogenic shock remains off-label; this case report leaves open its safety and role pending controlled data.
Chiu et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: